

Special Issue

Advances in Allergy Immunotherapy and Vaccination

Message from the Guest Editor

Allergic diseases are becoming increasingly detrimental to global health and economics. Classical allergic inflammation is caused by elevated allergen-specific IgE responses that promote basophil and mast cell degranulation upon encountering allergens. The only established disease-modifying treatment for allergic diseases—allergen-specific immunotherapy (AIT or SIT)—is not available for all types of allergies and still requires optimization from an efficacy/safety standpoint, as it currently requires a multitude of allergen extract injections over long time periods. Mechanistically, AIT aims to shift the type 2 inflammatory immune response towards a tolerant outcome. This Special Issue aims to improve our understanding of:

- The mechanisms that drive and suppress allergic sensitization and inflammation;
- The mechanisms by which allergic immune responses could be shifted towards tolerance by therapeutic vaccination and/or adjuvantation strategies;
- How the ability of allergens/vaccines to trigger the degranulation of mast cells and basophils could be reduced without losing their immunogenicity and their disease-modifying properties.

Guest Editor

Dr. Paul Engeroff

INSERM, Immunology-Immunopathology-Immunotherapy (i3),
Sorbonne Université, F-75005 Paris, France

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/124732

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).